About Us

Board of Directors

Andreas Segerros

Chairman

Bio-chemist by training and brings extensive commercial and business development experience from the global pharmaceutical corporations Pharmacia and Ferring where he has held executive positions in Europe, USA and Japan. Previously Venture Partner and Partner at Sunstone Capital in Denmark.

Börje Haraldsson

Professor, MD, PhD. Senior Global Program Head at Novartis, Basel, Switzerland since 2015. Professorship in Nephrology, Chair and senior Consultant at the University of Gothenburg and Sahlgrenska University Hospital, Sweden (2001-2015). Professor of Physiology (unpaid, since 2016) at the University of Gothenburg. Author of 150+ publications, world class clinical and research expertise, funded by the Swedish Research Council for 25 consecutive years with four years experience of leading global drug development in immunology.

Lena Mårtensson

PhD, Associate Professor in Physiology, Lund University, Sweden. Former Head Pipeline Sourcing Senior Director, LEO Pharma A/S. Former Director Strategic Planning and Business Development at AstraZeneca, several senior leadership positions at Pharmacia, Medical Director at Perstorp Pharma and Head of Preclinical R&D at Gambro. Board of Director of Genovis. Aqilion Partner.

Jenny Nyström

Professor in Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden. Expert in renal physiology and molecular mechanisms behind chronic kidney disease, instrumental in preclinical research and development.

Björn Odlander

MD, PhD from Karolinska Institutet, Sweden. Co-founder of HealthCap where he is managing partner since the start in 1996. Before that leading ABB Aros Securities Health Care Equity Research Team. He has extensive experience from multiple boards in the life-science sector including Q-Med AB, NicOx SA, Jerini AG, Nordic Nanovector ASA and BoneSupport AB.

Håkan Olsson

MD, PhD, Professor of Oncology, Lund University, Sweden. Research interest in cancer epidemiology and genetics, tumor biology, cancer prognosis and therapy. Published more than 500 scientific papers. Aqilion Partner.

Klementina Österberg

She has wide experience in building new companies. She is CEO of GU Ventures and chair of GOKAP. She has also experience from multiple boards in the life-science sector, including Alzinova, Cellink, Cereno, Metabogen, OnDosis, Ortoma, PExA and Toleranzia.